Vor Biopharma Reports Director Changes and Officer Appointments
Ticker: VOR · Form: 8-K · Filed: Aug 27, 2025 · CIK: 1817229
| Field | Detail |
|---|---|
| Company | Vor Biopharma Inc. (VOR) |
| Form Type | 8-K |
| Filed Date | Aug 27, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $119,699,305 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, governance, corporate-action
TL;DR
Vor Bio's 8-K: Director shake-ups, new officers, and votes on tap. Big changes ahead?
AI Summary
Vor Biopharma Inc. filed an 8-K on August 27, 2025, reporting on several key events as of August 25, 2025. These include the departure of directors or certain officers, the election of directors, the appointment of certain officers, and updates on compensatory arrangements. The filing also covers the submission of matters to a vote of security holders and other events, along with financial statements and exhibits.
Why It Matters
Changes in board composition and officer appointments can signal shifts in company strategy, leadership, and governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in directors and officers, especially if numerous or unexpected, can indicate internal challenges or strategic realignments that may pose risks.
Key Players & Entities
- Vor Biopharma Inc. (company) — Registrant
- August 25, 2025 (date) — Earliest event reported
- August 27, 2025 (date) — Date of report
FAQ
Who has departed from Vor Biopharma's board or officer positions?
The filing indicates the departure of directors or certain officers, but specific names are not detailed in this summary section.
Were any new directors or officers appointed by Vor Biopharma?
Yes, the filing reports on the election of directors and the appointment of certain officers.
What is the primary business of Vor Biopharma Inc.?
Vor Biopharma Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
What is the principal executive office address for Vor Biopharma?
The principal executive offices are located at 100 CambridgePark Drive, Suite 101, Cambridge, MA 02140.
What specific compensatory arrangements were discussed in the filing?
The filing mentions compensatory arrangements of certain officers, but the details are not provided in this summary.
Filing Stats: 1,070 words · 4 min read · ~4 pages · Grade level 12.2 · Accepted 2025-08-27 08:19:09
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share VOR Nasdaq Glob
- $119,699,305 — ng an aggregate offering price of up to $119,699,305 from time to time through or to Stifel,
Filing Documents
- d24419d8k.htm (8-K) — 37KB
- d24419dex51.htm (EX-5.1) — 10KB
- d24419dex101.htm (EX-10.1) — 167KB
- g24419g0826232830506.jpg (GRAPHIC) — 2KB
- 0001193125-25-189169.txt ( ) — 378KB
- vor-20250825.xsd (EX-101.SCH) — 3KB
- vor-20250825_lab.xml (EX-101.LAB) — 18KB
- vor-20250825_pre.xml (EX-101.PRE) — 11KB
- d24419d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 5.1 Opinion of Cooley LLP 10.1 Vor Biopharma Inc. Amended and Restated 2021 Equity Incentive Plan 23.1 Consent of Cooley LLP (contained in Exhibit 5.1) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Vor Biopharma Inc. Date: August 27, 2025 By: /s/ Jean-Paul Kress Jean-Paul Kress Chief Executive Officer